Lecture Details - Table of Contents

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Molecular Profiling and Decision Making in Breast Cancer: Clinical and Molecular Prognostic Information—Addressing Discordant Results

Release Date: December 30, 2008| Expiration Date: December 30, 2009
Dec 11, 2008, Online Learning Series Program 4

Table of Contents

1. Take the Pre-Test
Complete the pre-test by clicking on the "Take the Pre-Test" button
located in the upper right hand corner of this page under "Test Options"
before proceeding to the interview and expert faculty panel discussion.

2. An interview with cancer gene profiling pioneer Charles Perou. Expert panel discusses management when clinical and molecular risk assessments disagree.
Moderator: Debu Tripathy, MD
Matthew Ellis, MB BChir, PhD, FRCP
David M. Euhus, MD, FACS
Lori Goldstein, MD
Stephen Johnston, MD, PhD
Eleftherios Mamounas, MD, MPH, FACS
Charles Perou, PhD
Hope S. Rugo, MD

3. Take Home Messages
Debu Tripathy, MD

4. Reading List
Note: For your references.

5. Take the CME Test

  • Complete the CME test by clicking on the "Take the CME Test" button also located in the upper right hand corner of this page under "Test Options".

  • Answer all questions to complete this CME activity.

(View Previous Programs)

Additional PER Educational Activities on the Subject of Molecular Profiling include:

Lectures:


Publications:


Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate online.

CME credit will be granted for online participation only.
Successful completion is determined by a score of 75% or greater.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from Molecular Profiling and Decision Making in Breast Cancer online learning series: Program #4 activity have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Matthew Ellis, MB, BChir, PhD, FRCP
Research Funding — AstraZeneca; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Taiho Pharmaceutical Company, LTD.
Paid Consultant— AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Speaker’s Bureau— AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.

David M. Euhus, MD, FACS
No relevant relationships to disclose

Lori Goldstein, MD
Research Funding — AstraZeneca; Bristol-Myers Squibb Company; Genomic Health, Inc.; GlaxoSmithKline; Johnson & Johnson; Merck & Co., Inc.; sanofi-aventis U.S.; Wyeth Pharmaceuticals
Paid Consultant — Amgen; AstraZeneca; Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; Genomic Health, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmion Corporation; sanofi-aventis U.S.

Stephen Johnston, MD, PhD
Paid Consultant – AstraZeneca and GlaxoSmithKline
Research Funding – GlaxoSmithKline

Eleftherios Mamounas, MD, MPH, FACS
Paid Consultant – Genomic Health Inc. and Agendia
Speaker’s Bureau – Genomic Health Inc.

Charles Perou, PhD
Research Funding – Eli Lilly, Bristol-Myers Squibb Company, and Roche
Paid Consultant – Eli Lilly, Roche, and PharmaMar

Hope S. Rugo, MD
Speaker’s Bureau – AstraZeneca and Genomic Health, Inc.
Research Funding – Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Pharmaceuticals

Debu Tripathy, MD
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Molecular Profiling and Decision Making in Breast Cancer online learning series: Program #4
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Agendia